Profile data is unavailable for this security.
About the company
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
- Revenue in USD (TTM)10.50m
- Net income in USD-221.26m
- Incorporated2018
- Employees463.00
- LocationAutolus Therapeutics PLCThe Mediaworks, 191 Wood LaneLONDON W12 7FPUnited KingdomGBR
- Phone+44 203 829 6230
- Websitehttps://www.autolus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.12bn | 267.00 | -- | -- | -- | 2.71 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| MiMedx Group Inc | 334.51m | 71.52m | 1.15bn | 895.00 | 20.60 | 7.35 | 14.37 | 3.42 | 0.3767 | 0.3393 | 2.15 | 1.06 | 1.72 | 2.82 | 6.58 | 373,754.20 | 41.80 | -4.14 | 53.13 | -5.90 | 83.50 | 83.61 | 24.36 | -2.70 | 2.71 | 9.00 | 0.111 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
| Cullinan Therapeutics Inc | 0.00 | -132.35m | 1.16bn | 85.00 | -- | 2.04 | -- | -- | -3.14 | -3.14 | 0.00 | 9.88 | 0.00 | -- | -- | 0.00 | -27.85 | -12.37 | -29.31 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Arcutis Biotherapeutics Inc | 106.39m | -217.42m | 1.17bn | 296.00 | -- | 5.17 | -- | 10.96 | -2.91 | -2.91 | 1.30 | 1.95 | 0.248 | 0.6845 | 4.26 | 359,439.20 | -50.68 | -65.64 | -56.21 | -71.72 | 92.99 | -- | -204.36 | -1,513.03 | 9.61 | -6.52 | 0.4741 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 1.19bn | 309.00 | -- | 1.59 | -- | 33.59 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 1.22bn | 284.00 | -- | -- | -- | 29.28 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Autolus Therapeutics PLC (ADR) | 10.50m | -221.26m | 1.24bn | 463.00 | -- | -- | -- | 118.36 | -1.21 | -1.21 | 0.0564 | -- | 0.0154 | -- | 6.83 | 22,671.71 | -32.50 | -42.32 | -34.63 | -46.61 | -- | -- | -2,107.86 | -5,098.00 | -- | -4.39 | 0.00 | -- | -73.30 | -- | -40.01 | -- | -- | -- |
| Gyre Therapeutics Inc | 140.62m | -85.66m | 1.28bn | 593.00 | -- | 22.65 | -- | 9.13 | -1.88 | -1.88 | 1.55 | 0.663 | 2.00 | -- | 13.75 | 237,136.60 | -107.71 | -73.59 | -184.22 | -99.94 | 96.01 | -- | -53.91 | -205.62 | 2.97 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Enliven Therapeutics Inc | 0.00 | -79.60m | 1.28bn | 46.00 | -- | 4.02 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Prothena Corporation PLC | 89.25m | -172.40m | 1.31bn | 173.00 | -- | 2.61 | -- | 14.72 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Ardelyx Inc | 159.11m | -65.81m | 1.31bn | 267.00 | -- | 8.71 | -- | 8.26 | -0.2883 | -0.2883 | 0.7007 | 0.6449 | 0.5689 | 3.20 | 7.90 | 595,917.60 | -23.53 | -46.14 | -29.95 | -57.32 | 85.30 | 88.15 | -41.36 | -240.87 | 4.36 | -9.86 | 0.3982 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Xencor Inc | 162.18m | -133.36m | 1.33bn | 280.00 | -- | 2.18 | -- | 8.23 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Disc Medicine Inc | 0.00 | -80.60m | 1.35bn | 74.00 | -- | 3.34 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.40bn | 174.00 | -- | 4.72 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Data as of Jul 26 2024. Currency figures normalised to Autolus Therapeutics PLC's reporting currency: US Dollar USD
37.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Syncona Investment Management Ltd.as of 31 Mar 2024 | 21.35m | 8.02% |
| Deep Track Capital LPas of 31 Mar 2024 | 15.27m | 5.74% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 12.35m | 4.64% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 10.56m | 3.97% |
| TFG Asset Management UK LLPas of 31 Mar 2024 | 7.53m | 2.83% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 6.79m | 2.55% |
| Cormorant Asset Management LPas of 31 Mar 2024 | 6.62m | 2.49% |
| Link Fund Solutions Ltd.as of 30 Jun 2019 | 6.56m | 2.47% |
| Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 6.43m | 2.42% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 5.49m | 2.06% |
More ▼
Data from 28 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
